drugset / Trial / NCT05419674
Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy of dual therapy compared with bismuth-containing quadruple therapy as first-line treatment for Helicobacter Pylori eradication, as well as the safety and economic benefits.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Comparator | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Rabeprazole | Small molecule | 10 mg | — |
| Subject | Vonoprazan | Other / unclassified | 20 mg | — |
| Comparator | colloidal bismuth pectin | Unknown | 200 mg | — |